Aducanumab in early Alzheimer’s disease: topline results from two phase 3 trials

Topline results from two phase 3 trials, presented at AAIC 2020, have provided insight into the efficacy of aducanumab in patients with early Alzheimer’s disease (AD).

Aducanumab is monoclonal antibody that targets aggregated forms of Aβ, including soluble oligomers and insoluble fibers.